ID: h-b2b732cd07
Hypothesis
RGS6 isoform switching or small-molecule RGS6 activation as disease-modifying therapy
Pursue either isoform-specific RGS6 engineering or pharmacologic RGS6 activation to enhance protective signaling.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 3 oppose
🧪 Overview
Pursue either isoform-specific RGS6 engineering or pharmacologic RGS6 activation to enhance protective signaling. The debate strongly argues these are premature because core isoform biology, target engagement, selectivity, and safety are not established.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["RGS6 Expression<br/>G Protein Signaling Regulator"]
B["GIRK Channel<br/>Regulation"]
C["Dopamine Signaling<br/>Modulation"]
D["Neural Excitability<br/>Control"]
E["RGS6 as<br/>Neural Circuit Target"]
F["RGS6-Based<br/>Therapeutic Modulation"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Supports
RGS6 is a mechanistically central node in the source phenotype, so more selective modulation remains conceptually attractive if foundational biology can be established.
Supports
RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Supports
Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra.
Contradicts
The cited splice literature supports isoform diversity but not the claimed mitochondrial-targeted RGS6+2 therapeutic mechanism in adult SNpc neurons.
Contradicts
The RGS druggability literature emphasizes that isoform-selective, brain-penetrant activators are not established and the field is far more advanced for inhibitors than activators.
Contradicts
Potential pro-apoptotic liabilities further weaken enthusiasm for activation strategies before careful target-biology resolution.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — RGS6
No curated PDB or AlphaFold mapping for RGS6 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for RGS6 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for RGS6.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 1.3%
Volatility
High
0.0959
Events (7d)
2
Price History
▲64.6%💾 Resource Usage
LLM Tokens
11,782
$0.0353
Total Cost
$0.0353
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF WT rats receive daily intraperitoneal injections of a selective small-molecule RGS6 activator (BT-11, 10 mg/kg) starting 1 week before and continuing 4 weeks after 6-OHDA medial forebrain bundle le | ≥40% reduction in net ipsilateral rotations; ≥30% increase in striatal tissue dopamine via HPLC-EC | — no observation — | pending | 0.28 |
| IF neuron-specific RGS6 is genetically overexpressed in C57BL/6 mice prior to chronic MPTP administration (40 mg/kg cumulative over 5 days), THEN motor performance on accelerating rotarod will improve | ≥25% improvement in rotarod latency; ≥35% increase in stereological TH+ neuron count in substantia nigra pars compacta | — no observation — | pending | 0.35 |
🔮 Falsifiable Predictions (2)
pendingconf 35%
IF neuron-specific RGS6 is genetically overexpressed in C57BL/6 mice prior to chronic MPTP administration (40 mg/kg cumulative over 5 days), THEN motor performance on accelerating rotarod will improve by ≥25% and striatal TH+ dopaminergic neuron survival will increase by ≥35% compared to MPTP-treate
Predicted outcome: ≥25% improvement in rotarod latency; ≥35% increase in stereological TH+ neuron count in substantia nigra pars compacta
Falsification: No statistically significant difference (p > 0.05) in rotarod performance or TH+ neuron survival between RGS6-overexpressing and control MPTP-treated mice
pendingconf 28%
IF WT rats receive daily intraperitoneal injections of a selective small-molecule RGS6 activator (BT-11, 10 mg/kg) starting 1 week before and continuing 4 weeks after 6-OHDA medial forebrain bundle lesion, THEN amphetamine-induced rotational asymmetry will decrease by ≥40% and striatal dopamine cont
Predicted outcome: ≥40% reduction in net ipsilateral rotations; ≥30% increase in striatal tissue dopamine via HPLC-EC
Falsification: Rotational asymmetry not significantly reduced (p > 0.05) and striatal dopamine not significantly elevated in BT-11-treated vs vehicle-treated 6-OHDA rats
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.